RecruitingPhase 3NCT05201404
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Can-Fite BioPharma
- Principal Investigator
- Michael H Silverman, MDBioStrategics Consulting Ltd
- Intervention
- Namodenoson(drug)
- Enrollment
- 471 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Site 881, Dallas, Texas, United States
- 841 University Clinical Centre of Republic of Srpska, Banja Luka, Bosnia and Herzegovina
- 843 University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
- 842 University Clinical Centre Sarajevo, Sarajevo, Bosnia and Herzegovina
- 831 Dept of Medical Oncology, Complex Oncology Ctr - Burgas EOOD, Burgas, Bulgaria
- 835 First Department of Medical Oncology, Gastroenterology and Pulmology, Complex Oncology Center - Plovdiv EOOD, Plovdiv, Plovdiv, Bulgaria
- Medical Center Leo Clinic EOOD Plovdiv, Plovdiv, Bulgaria
- 834 Medical Oncology Dept, Univ Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Sofia, Sofia, Bulgaria
- 518 Rabin Medical Center Beilinson Hospital, Petah Tikva, Israel
- 872 IMSP Institute of Oncology, Chisinau, Moldova
- Site 858, Koszalin, Poland
- Site 852, Krakow, Poland
- Site 857, Mysłowice, Poland
- Site 859, Przemyśl, Poland
- Site 855, Warsaw, Poland
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05201404 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital